Peptide Synthesis: How Peptides Are Made

Key Takeaways

• Dominant method: Solid-phase peptide synthesis (SPPS), developed by Nobel laureate Bruce Merrifield in the 1960s, is the primary method for producing both research and therapeutic peptides today.
• Two main strategies: Fmoc chemistry (mild base deprotection, preferred for most applications) and Boc chemistry (strong acid deprotection, used for specialized cases and historically the original SPPS approach).
• Length limitation: SPPS alone is reliable for sequences up to roughly 50 amino acids; native chemical ligation (NCL) joins SPPS-produced fragments to assemble longer peptides and full proteins.
• Biological alternatives: Recombinant expression and enzymatic synthesis offer routes to longer or post-translationally modified peptides that chemical synthesis cannot easily access.
• Quality matters: Synthesis purity and process quality directly determine whether a peptide has the intended identity, potency, and impurity profile; pharmaceutical-grade synthesis differs fundamentally from unregulated research-compound production.

What Peptide Synthesis Is

Peptide synthesis is the controlled assembly of amino acids into a defined sequence through covalent peptide bond formation. The goal is to produce a specific molecular entity, amino acid by amino acid, in a predetermined order — because sequence determines structure, and structure determines biological function. A peptide synthesized in the wrong sequence, or with racemized amino acids, or with residual protecting-group fragments, is not the intended molecule. This precision requirement distinguishes peptide synthesis from most other areas of organic chemistry.

The fundamental chemistry is a condensation reaction: the carboxyl group of one amino acid reacts with the amino group of the next, releasing one water molecule per bond and creating an amide linkage. The directional chain that results has a free amino group at one end (N-terminus) and a free carboxyl group at the other (C-terminus). The practical challenge of building this chain is preventing every amino acid's reactive groups from participating in unwanted reactions during assembly — which is the problem that protecting-group chemistry and, ultimately, solid-phase synthesis were designed to solve.

Discovery and history

The foundational challenge of chemical peptide synthesis was recognized in the early twentieth century, and early solution-phase methods by workers including Bergmann, Zervas, and others required laborious purification of intermediates at each step. The field was transformed in 1963 when Robert Bruce Merrifield reported the first solid-phase method in the Journal of the American Chemical Society. Merrifield, in foundational work published in Advances in Enzymology in 1969, described anchoring the C-terminal amino acid to a solid resin and adding protected amino acids sequentially, washing away reagents and byproducts between each step without removing the growing chain from the support. This eliminated the purification problem that had made prior methods impractical for peptides beyond a few residues. Merrifield was awarded the Nobel Prize in Chemistry in 1984. An authoritative early review by Fridkin and Patchornik, published in the Annual Review of Biochemistry in 1974, documented how the new solid-phase methodology was transforming the practical scope of peptide chemistry within a decade of its introduction.

How Solid-Phase Peptide Synthesis Works

SPPS proceeds through a cycle: protect, couple, deprotect, repeat. Each cycle adds one amino acid residue to the growing chain. The peptide remains attached to the resin throughout and is cleaved only at the end of the full synthesis. This allows washing steps between each cycle to remove excess reagents and byproducts without losing the growing chain — the central operational advantage that Merrifield's solid-phase concept introduced.

Fmoc chemistry: the current standard

The Fmoc (9-fluorenylmethoxycarbonyl) strategy is the dominant approach in modern SPPS. Each incoming amino acid arrives with its alpha-amino group protected by an Fmoc group and its side chains protected by acid-labile groups. The coupling step forms a peptide bond between the incoming amino acid's carboxyl group and the free amino group of the chain's N-terminal residue, assisted by coupling reagents that activate the carboxyl group. The Fmoc group is then removed by treatment with piperidine (a mild base), revealing a new free amino group for the next coupling step. A comprehensive review by Behrendt, White, and Offer, published in the Journal of Peptide Science in 2016, established Fmoc SPPS as the preferred methodology for therapeutic peptide manufacturing, citing its compatibility with acid-labile side-chain protecting groups, the mild deprotection conditions that reduce side-chain damage, and the extensive range of commercially available Fmoc amino acid building blocks that simplifies synthesis setup.

The connection to health is direct: FDA-approved synthetic peptide drugs across major classes — including the GLP-1 receptor agonists at the center of obesity medicine and the GnRH analogs used in oncology — are produced by processes that evolved from this chemistry.

Boc chemistry: the original SPPS strategy

The original SPPS strategy used Boc (tert-butyloxycarbonyl) as the temporary amino-protecting group, removed with trifluoroacetic acid at each cycle and with anhydrous HF for final cleavage from the resin. Boc chemistry was the standard method for decades and remains in use for specialized applications, including synthesis of acid-stable sequences and certain non-natural amino acid incorporations. The Boc approach requires working with HF, a hazardous reagent, and the repeated acidic deprotection cycles can pose greater risk of side reactions for acid-sensitive residues. For most current therapeutic peptide manufacturing, Fmoc has replaced Boc as the workhorse chemistry, though orthogonal strategies combining both protecting groups find use in complex branched peptides. Cavallaro and colleagues, in work published in the Journal of Peptide Science in 2001, described combined Boc and Fmoc strategies for synthesizing complex branched peptides that neither scheme could access alone.

Resin attachment, linkers, and cleavage

The peptide is anchored to the resin through a linker group that determines both the stability of attachment during synthesis and the conditions required for cleavage at the end. Most linkers cleave under the same acidic conditions used to remove side-chain protecting groups, releasing the fully deprotected peptide in a single step. Safety-catch linkers offer an additional selectivity layer: they remain stable during all deprotection cycles and are activated for cleavage only by a specific chemical trigger applied at the synthesis end. Noki, de la Torre, and Albericio, writing in Molecules in 2024, reviewed safety-catch linkers compatible with both Boc and Fmoc strategies, and Ferrer-Gago and Koh, writing in ChemPlusChem in 2020, covered specialized linker strategies for alcohol-containing peptide syntheses requiring orthogonal protection. Linker chemistry determines whether C-terminal modifications such as thioesters — essential for downstream ligation — can be produced efficiently.

The practical health relevance: the linker and cleavage conditions affect whether impurities from the resin or protecting groups remain in the final product. Pharmaceutical-grade manufacturing specifies these steps precisely and verifies the final peptide by analytical methods (HPLC, mass spectrometry) before any product is used in humans.

Extending Length Limits: Native Chemical Ligation

SPPS becomes progressively less efficient as peptide length increases. Side reactions accumulate across more coupling cycles; aggregation of the growing chain on the resin can impair further coupling; overall yields decline. In practice, reliable high-purity SPPS is typically achievable for sequences up to approximately 50 amino acids, though the practical ceiling depends on the specific sequence and synthetic conditions. This constraint matters because biologically active proteins — including growth hormone at 191 amino acids and many enzymes — far exceed that length.

NCL: joining SPPS fragments chemoselectively

Native chemical ligation (NCL) solves the length problem by dividing a long target sequence into smaller fragments, each synthesized independently by SPPS, and then joining them in a defined order through a chemoselective reaction. Each ligation joins a fragment bearing a C-terminal thioester to a fragment bearing an N-terminal cysteine. The reaction proceeds spontaneously in aqueous solution without any protecting groups, proceeding through a transthioesterification followed by intramolecular S-to-N acyl shift that forms a native amide (peptide) bond at the junction. A comprehensive review by Conibear, Watson, Payne, and Becker, published in Chemical Society Reviews in 2018, established NCL as the method for joining SPPS fragments into full proteins, enabling the total chemical synthesis of proteins including insulin, ubiquitin, and HIV protease from peptide building blocks. Kent, in an authoritative review in Bioorganic and Medicinal Chemistry in 2017, described the chemoselective condensation approach with examples including insulin and HIV protease synthesis, demonstrating how sequences impossible to build by SPPS alone become accessible through convergent chemical assembly. Raibaut, Ollivier, and Melnyk, writing in Chemical Society Reviews in 2012, reviewed sequential ligation approaches to total protein synthesis from peptide fragments. Giesler, Erickson, and Kay, writing in Current Opinion in Chemical Biology in 2020, addressed methods for ligating difficult sequences where standard NCL chemistry is inefficient.

The result is that the boundary between what chemistry can build and what biology builds has become navigable. Fully synthetic insulin — produced entirely by SPPS and NCL without any biological expression system — is scientifically feasible in academic demonstrations today. All commercially available insulin is recombinantly produced.

Acyl donor chemistry and Fmoc-NCL compatibility

Early NCL relied on Boc chemistry to produce C-terminal thioesters, because Fmoc deprotection conditions hydrolyze standard thioesters. Subsequent work developed Fmoc-compatible thioester surrogates — precursors that are stable under Fmoc synthesis conditions but convert to thioesters upon activation. Thomas, writing in the Journal of Peptide Science in 2013, described Fmoc-compatible thioester synthesis enabling parallel ligation. Tailhades and colleagues, in the Journal of Peptide Science in 2015, reviewed acyl transfer chemistry in peptide ligation, providing mechanism detail on how different ligation approaches achieve native bond formation. Yan, Shi, Ye, and Liu, writing in Current Opinion in Chemical Biology in 2018, reviewed acyl donor chemistry for NCL, covering the range of thioester precursor strategies now available under both Boc and Fmoc chemistry regimes. This expansion of compatible chemistry means NCL is now accessible from either SPPS strategy.

Biological Synthesis Methods

Chemical synthesis is not the only route to peptides. Several biological production methods are used in research and manufacturing, each with distinct advantages and constraints relative to SPPS and NCL.

• Recombinant expression:
  • Principle: A DNA sequence encoding the target peptide is inserted into an expression vector and introduced into a host organism (commonly E. coli, yeast, or mammalian cells), which transcribes and translates the sequence using its own ribosomal machinery.
  • Advantages: Scalable for large proteins; allows post-translational modifications (glycosylation, disulfide bond formation) that chemical synthesis cannot reproduce for complex targets.
  • Limitations: Limited control over N- and C-terminal modifications; post-translational modifications depend on host biology; cost-competitive primarily for larger proteins, not short peptides.
• Enzymatic and cell-free synthesis:
  • Principle: Enzymatic hydrolysis of proteins produces short peptide fragments; cell-free translation systems using ribosomes, tRNA, and aminoacyl-tRNA synthetases can assemble peptides from defined substrates without living cells.
  • Advantages: Enzymatic hydrolysis produces bioactive peptide libraries from food proteins or protein precursors at low cost; cell-free ribosomal systems allow incorporation of non-standard amino acids using engineered tRNA.
  • Limitations: Enzymatic hydrolysis produces heterogeneous fragments, not defined sequences; cell-free synthesis throughput is currently limited for pharmaceutical scale.
• Ribosomal synthesis with genetic code expansion:
  • Principle: Engineered organisms or cell-free systems incorporate non-standard amino acids at defined positions by reassigning codons or suppressing stop codons, using engineered aminoacyl-tRNA synthetase-tRNA pairs.
  • Advantages: Allows genetically encoded incorporation of fluorescent labels, reactive handles, and non-proteinogenic residues that are difficult or impossible to incorporate by SPPS.
  • Limitations: Complex system engineering required; efficiency depends on suppression strategy and host compatibility.

A review by Deo and colleagues, published in Biotechnology Advances in 2022, compared SPPS, recombinant expression, and enzymatic methods for antimicrobial peptide production across yield, cost, and applicability criteria. Katoh and Suga, writing in Nature Reviews Chemistry in 2024, reviewed ribosomal peptide synthesis with engineered tRNA for non-standard amino acid incorporation, illustrating how the boundary between chemical and biological synthesis continues to be refined. In current pharmaceutical manufacturing, SPPS remains the method of choice for peptides up to approximately 50 residues; recombinant expression is used for larger biologics; and hybrid chemical-biological strategies, including semisynthesis, are applied where neither method alone provides sufficient efficiency or structural control.

What the Evidence Shows

The body of evidence on peptide synthesis methodology reflects decades of systematic chemistry research rather than clinical trials. The key landmarks are technological rather than therapeutic: the invention of SPPS (Merrifield, 1963), the development of Fmoc chemistry (Carpino and Han, 1972), the introduction of NCL (Dawson, Muir, Clark-Lewis, and Kent, 1994), and the subsequent expansion of each methodology to address specific synthesis challenges.

Berillo and colleagues, reviewing peptide-based drug delivery systems in Medicina (Kaunas) in 2021, illustrated how synthesis-derived material properties shape pharmaceutical usefulness. Sharma and colleagues, in a review published in Drug Discovery Today in 2023, traced the peptide development pipeline from synthesis to clinical evaluation, showing how each step from SPPS through preclinical and clinical assessment narrows a large synthesis space to a small set of approved medicines. Erak and colleagues, reviewing medicinal peptide applications in Bioorganic and Medicinal Chemistry in 2018, showed how solid-phase development enabled chemical modifications including cyclization, D-amino acid substitution, and PEGylation that give synthetic peptides pharmacokinetic properties unavailable to purely biological sequences. Obexer and colleagues, in a 2024 Science review of therapeutic oligonucleotide manufacturing, described scaling pressures analogous to those facing peptide manufacturing.

Environmental and industrial-scale considerations

Large-scale SPPS generates significant solvent waste, particularly dimethylformamide (DMF), the standard solvent for Fmoc chemistry. Environmental sustainability has become an active area of synthesis research. Varnava and Sarojini, writing in Chemistry: An Asian Journal in 2019, reviewed environmentally sustainable approaches to SPPS, including replacement of DMF with greener solvents such as dimethyl isosorbide and cyclopentyl methyl ether, and reported comparable synthesis efficiencies with significantly reduced toxicity. As therapeutic peptide demand grows with the expanded use of GLP-1 class agents and other peptide drugs, synthesis scale and environmental impact have become commercially and regulatorily relevant considerations.

Post-synthesis modification workflows

Many therapeutic peptides require chemical modifications after chain assembly to achieve the pharmacokinetic properties needed for clinical use. PEGylation (attachment of polyethylene glycol chains) reduces renal clearance and extends half-life. Lipidation (fatty acid attachment) enables formulation for subcutaneous injection and prolongs duration of action. Disulfide bond formation (for peptides containing cysteines) establishes the three-dimensional structure required for receptor recognition. Chemoenzymatic approaches, reviewed by Ochiai and colleagues in ChemMedChem in 2024, describe enzymatic glycopeptide production workflows combining chemical synthesis with enzymatic glycosylation to produce glycopeptide therapeutics that cannot be assembled by chemistry alone. Drucker, in a landmark review in Nature Reviews Drug Discovery in 2020, examined how peptides manufactured by SPPS overcome gastrointestinal barriers through chemical modifications including permeation enhancers and cell-penetrating peptide conjugates — linking the chemistry of synthesis directly to the clinical challenge of oral peptide delivery.

How Synthesis Connects to Measurable Biomarkers

Peptide synthesis is a manufacturing process, not a clinical intervention — so the biomarker connections are indirect but consequential. The peptides produced by synthesis become the medicines and research tools through which biology, measured in bloodwork, is studied and modified. For anyone using or evaluating peptide-based therapies, understanding whether a product was produced by pharmaceutical-grade synthesis has direct implications for what the product actually is.

• IGF-1: The primary downstream marker of growth hormone axis activity. Growth hormone secretagogues — peptides produced by SPPS — are studied in part through their effects on IGF-1. A baseline IGF-1 measurement gives objective context for evaluating any GH-axis intervention.
• Glucose and HbA1c: The most widely used endpoints in clinical trials of GLP-1 receptor agonists. Semaglutide (FDA-approved for type 2 diabetes and chronic weight management) and liraglutide (FDA-approved for type 2 diabetes and chronic weight management) are both SPPS-produced synthetic peptides. Baseline and follow-up glucose and HbA1c measurements define the metabolic context in which these approved peptide drugs are evaluated in clinical practice.
• hs-CRP: A systemic inflammatory marker relevant when evaluating anti-inflammatory peptides or peptide-based immunomodulators. Synthesis quality determines whether the intended peptide, not an impurity, is responsible for any observed effect on inflammatory markers.

The metabolic health biomarker testing guide covers the markers most directly relevant to understanding your biology before exploring any peptide-based intervention.

When to Take This Seriously

Peptide synthesis quality has direct clinical consequences. Insulin produced by pharmaceutical-grade synthesis has a defined purity and potency; the same amino acid sequence produced under uncontrolled conditions does not. Documented adverse event cases from unregulated research peptides have generally involved products manufactured outside the pharmaceutical standards that validated peptides are held to. The synthesis method and manufacturing controls are not secondary details — they are what determines whether a peptide product is the molecule it claims to be.

For clinicians and patients evaluating peptide therapies, the synthesis origin of any product matters: pharmaceutical-grade products have documented synthesis procedures, analytical characterization, and lot-to-lot consistency standards. Products sold through unregulated channels carry no such verification. This distinction applies regardless of how well-characterized the underlying chemistry is.

Understanding the molecular biology that connects peptide structure to function is foundational to evaluating any health claim made about a peptide compound. That framework, grounded in objective data rather than marketing context, is central to Superpower's approach to preventive health.